CMF-019
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H33N3O3S |
| Molar mass | 455.62 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CMF-019 is a drug which is a selective, small-molecule agonist for the apelin receptor. It is used in research into treatment for heart failure.[1][2][3]
See also
References
- ^ Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, et al. (September 2016). "Cardiac action of the first G protein biased small molecule apelin agonist". Biochemical Pharmacology. 116: 63–72. doi:10.1016/j.bcp.2016.07.018. PMC 5012889. PMID 27475715.
- ^ Trifonov L, Afri M, Palczewski K, Korshin EE, Gruzman A (2018). "An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist". Medicinal Chemistry. 14 (7): 688–694. doi:10.2174/1573406414666180412154952. PMC 6993063. PMID 29651942.
- ^ Narayanan S, Vasukuttan V, Rajagopal S, Maitra R, Runyon SP (February 2020). "Identification of potent pyrazole based APELIN receptor (APJ) agonists". Bioorganic & Medicinal Chemistry. 28 (4) 115237. doi:10.1016/j.bmc.2019.115237. PMC 7055011. PMID 31948845.